James Smith on Mounjaro: what the clinical evidence says

What the trial data says, and why NICE took it seriously

The SURMOUNT-1 study randomised 2,539 adults with obesity, without type 2 diabetes, to tirzepatide or placebo over 72 weeks, all alongside a reduced-calorie diet and increased physical activity. At the highest dose, average body-weight reduction was around 20–21%. Those are not figures plucked from a press release; they come from the peer-reviewed paper published in the New England Journal of Medicine, and they were scrutinised closely when NICE evaluated the medicine.

NICE published its recommendation (Technology Appraisal TA1026) in December 2024. Independent appraisal committees do not endorse medicines lightly: they weigh trial quality, the size and duration of effects, safety signals, and whether the benefit is likely to hold in NHS clinical practice. Tirzepatide passed that bar. That context matters when assessing arguments that the evidence for these medicines is weak or overstated.

One point that sometimes gets lost: trial participants were not simply injecting and eating whatever they liked. Diet coaching and activity support ran alongside treatment in every arm of the study. The medicine reduced appetite significantly, which made calorie reduction easier, but the lifestyle component was real. Commentators who frame GLP-1 medicines as replacing effort are misreading the trial design, and if you are curious about the various names tirzepatide is known by across different contexts, that page clarifies the terminology. Explore the full evidence profile on the tirzepatide overview.

Where critics raise fair points, and where the evidence pushes back

James Smith's core argument tends to be that obesity is addressable through diet and training, and that medicalising it risks creating dependency or side-stepping root causes. That is a legitimate philosophical position held by some clinicians too. The evidence, though, complicates it.

Long-standing research shows that the body actively defends its weight after loss, through hormonal and metabolic adaptations that persist for years. The NHS medicines guidance on tirzepatide notes it works by activating gut-hormone receptors involved in appetite and blood-sugar regulation, in other words, it addresses a physiological mechanism, not simply willpower. For many people, that mechanism has been working against them despite sustained effort.

The dependency question is real and worth taking seriously. Weight often returns when treatment stops, which is why prescribers discuss long-term plans, and why the clinical conversation does not end at the prescription. What the evidence does not support is the idea that people using Mounjaro are avoiding the hard work; in trials, they did the hard work and got better results because a hormonal barrier was lowered. If you have seen Mounjaro referred to by different names and want to know what they all refer to, the page covering the other names Mounjaro goes by brings that together clearly. The Mounjaro treatment page covers the mechanism in more detail.

Who Mounjaro is and isn't for, and how clinical suitability is determined

Mounjaro carries a UK licence for adults with a BMI of 30 or above, or 27 or above alongside a relevant condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not settle the matter: prescribers look at the full picture, including medical history, current medicines and any contraindications.

It is not licensed for use during pregnancy, breastfeeding or when trying to conceive, and it is not prescribed to anyone under 18. People with a personal or family history of medullary thyroid carcinoma, or certain pancreatic conditions, need a careful prescriber conversation before any GLP-1 medicine is considered. Patients sometimes ask about the generic names associated with Mounjaro, which is a useful starting point for understanding how the medicine fits into the broader drug landscape. The weight-loss treatment overview sets out the landscape of available options, including how the different licensed medicines compare.

If you are weighing up whether Mounjaro is appropriate for your circumstances, that decision belongs with a prescriber who can review your health history, not a fitness influencer's video, however well-intentioned. Questions about what treatment costs privately, and what those costs include, come up often; that page answers them plainly. For a fuller picture of how the consultation works and what our clinical team reviews, the clinical team profile is a good starting point.

Getting this right: the consultation, the prescriber, and what actually arrives

If a clinician approves treatment following your consultation, what arrives is a plain, unbranded box via DPD tracked delivery the next working day, inside, the KwikPen itself, which holds four weekly doses and requires no assembly. There is nothing to suggest to a neighbour what is in the parcel.

The more important point is what happens before the box leaves. At nume, a GPhC-registered Independent Prescriber reads your consultation the same day; a real clinician, not automated software, makes the clinical call. Identity and weight are verified. That process exists because Mounjaro is a prescription-only medicine, and the clinical assessment is not a formality, it is the mechanism that keeps people safe.

Aftercare continues once treatment starts: prescribers are available seven days a week, and every repeat order is reviewed before dispatch. If you want to understand the full process before deciding anything, the FAQs page answers the questions our prescribers hear most often. When you are ready to see whether you are eligible, you can check your eligibility with a free consultation.